Research
as of Mar. 21, 2024
The following table outlines the total external research grant funding and national rank. Through analysis of these data, the School can assess and monitor performance to ensure that the research enterprise is optimized to deliver on its intended outcomes relative to the School’s strategic plan.
| Federal Fiscal Year | Total external research grant funding | Rank based on total external research grant funding | NIH research grant funding* | Rank based on NIH research grant funding |
|---|---|---|---|---|
| 2023* | $86,084,121 | $65,046,075 | ||
| 2022* | $75,082,027 | $59,946,906 | ||
| 2021 | $48,683,211 | 2 | $34,001,726 | 2 |
| 2020 | $46,068,975 | 2 | $32,313,956 | 2 |
| 2019 | $39,000,650 | 2 | $30,342,787 | 2 |
| 2018 | $37,011,727 | 2 | $28,503,143 | 2 |
| 2017 | $38,192,834 | 2 | $25,356,453 | 2 |
| 2016 | $36,342,302 | 2 | $24,808,108 | 2 |
| 2015 | $26,896,175 | 2 | $20,379,328 | 2 |
| 2014 | $20,926,094 | 3 | $16,166,252 | 3 |
| 2013 | $22,652,829 | 2 | $18,856,551 | 2 |
| 2012 | $27,730,710 | 2 | $23,526,222 | 3 |
| 2011 | $25,235,610 | 2 | $21,010,624 | 3 |
| 2010 | $24,327,406 | 3 | $21,902,086 | 2 |
| 2009 | $24,924,362 | 4 | $22,935,797 | 2 |
| 2008 | $24,471,628 | 2 | $21,182,935 | 2 |
| 2007 | $13,270,072 | 6 | $10,372,364 | 6 |
| 2006 | $12,350,014 | 6 | $9,720,414 | 7 |
| 2005 | $6,905,485 | 15 | $6,905,485 | 11 |
| 2004 | $6,565,996 | 15 | $6,051,595 | 12 |
| 2003 | $4,278,656 | 24 | $3,913,665 | 21 |
| 2002 | $3,790,080 | 21 | $2,579,077 | 26 |
Data represents total external research grant funding and NIH grant funding (which includes CoI/CoPI NIH funding), independently verified by the American Association of Colleges of Pharmacy (AACP). The data is reported each Federal Fiscal Year (October 1 to September 30) by the Eshelman School of Pharmacy Director of Research Administration. Data is shared with AACP in January and is typically available for reporting via the AACP website by late May to mid-June each year.
* Indicates data submitted to AACP but not finalized or published.
Authoritative Data Source
- Director of Research Administration and AACP Final Report
as of Mar. 21, 2024
The following table outlines the annual and overall success rate in funded proposals for external research funding by category. Through analysis of these data, the School can assess and monitor performance to ensure that the research enterprise is optimized to deliver on its intended outcomes relative to the School’s strategic plan.
| Fiscal Year | All % | Federal US (%) | Business and Industry (%) | Association (%) | Nonprofit Organizations (%) | Foundation (%) | Educational and Research Institution (%) | Federal Non-US (%) |
|---|---|---|---|---|---|---|---|---|
| Overall Win Rate (1) | 35 | 25 | 50 | 45 | 51 | 37 | 30 | 27 |
| 2023 | 39 | 28 | 54 | 29 | 47 | 48 | 27 | 0 |
| 2022 | 37 | 30 | 47 | 71 | 76 | 57 | 11 | 0 |
| 2021 | 36 | 24 | 65 | 57 | 55 | 36 | 24 | 0 |
| 2020 | 32 | 22 | 47 | 22 | 41 | 38 | 34 | 100 |
| 2019 | 32 | 25 | 40 | 38 | 50 | 27 | 32 | 100 |
| 2018 | 30 | 21 | 37 | 67 | 50 | 27 | 32 | 0 |
| 2017 | 35 | 26 | 48 | 30 | 41 | 39 | 33 | 17 |
| 2016 | 41 | 23 | 62 | 57 | 50 | 30 | 52 | 0 |
Note – The data represents proposal types that are New, Renewal (Competitive), Resubmission or Amendment, Revision (Competitive), or Supplement.
(1) The overall win rate is the sum of all awards received in previous years reported divided by proposals made in all previous years reported. Award total received in the year are based on award notice date and unique award number divided by proposals made in year as reported in RAMSeS. Unique proposal numbers are anchored to unique award numbers. The following proposal types are excluded from this analysis – Non-Competing Continuation/Progress Report and Recurring Contracts.
Authoritative Data Source – Report Catalog / Custom Reports